BELLUS Health Inc. (TSE:BLU – Get Free Report) fell 0.1% during trading on Tuesday . The stock traded as low as C$19.24 and last traded at C$19.48. 28,666 shares traded hands during trading, a decline of 52% from the average session volume of 59,471 shares. The stock had previously closed at C$19.50.
BELLUS Health Stock Performance
The company’s 50 day moving average is C$19.48. The company has a market cap of C$2.47 billion, a P/E ratio of -20.29 and a beta of -0.28. The company has a quick ratio of 16.40, a current ratio of 33.42 and a debt-to-equity ratio of 0.32.
About BELLUS Health
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Featured Articles
- Five stocks we like better than BELLUS Health
- When to Sell a Stock for Profit or Loss
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- How to Capture the Benefits of Dividend Increases
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
